U.S. Stem Cell reported a 106 percent revenue increase for the third quarter of 2017, reflecting a surging demand for stem cell treatments at its clinics.
Here are four things to know:
1. Total revenue for 2017 will be announced in mid-March when the company files its 10k and is expected to increase from 2016.
2. Since 1999, U.S. Stem Cell has been involved in more than 10,000 stem cell procedures for indications including orthopedic, autoimmune, degenerative and neurological diseases. The company has also trained and certified over 700 physicians and veterinarians worldwide in stem cell therapy. Over 287 clinics use its proprietary technology.
3. U.S. Stem Cell Chief Science Officer Kristin Comella, PhD, identifies the primary factors driving the company's growth as the failure of opioid protocols to manage chronic pain and improved economic conditions, as stem cell therapy is an out-of-pocket expense.
4. Dr. Comella was instrumental in developing and bringing U.S. Stem Cell's lead product Adipocell to market. Adipocell is a stem cell kit which allows physicians to separate potent stem cells from a patient's fat cells, which are harvested and reinserted during a minimally invasive two hour procedure without general anesthesia.
Orthocell's CelGro collagen rope may be superior option for ACL reconstruction: 4 key insights
CartiHeal secures $2.5M from Bioventus, financing reaches $21M — 3 key insights